Clinical trial
Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or…
NCT00058045 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00058045 |
|---|---|
| Title | Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer |
| Official title | A Phase I Study Of Low-Dose Subcutaneous Interleukin 2 (IL-2) And Stem Cell Factor (r-metHuSCF) For Patients With AIDS And AIDS-Associated Malignancy |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | aldesleukin, recombinant human stem cell factor |
| Enrollment | 1 |
| Start date | Aug 1, 2002 |
| Primary completion | Nov 1, 2003 |
| First posted | Apr 9, 2003 |
| Last update posted | Jan 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: